Regulatory Classification Challenges
New regulatory categories for interventions that blur the lines between drug, device, and lifestyle.
Traditional regulatory pathways (FDA) are designed for treating diseases, not aging itself. This framework proposes new classes of 'geroprotectors' or 'healthspan enhancers' that allow for the approval of therapies based on biomarker improvements (e.g., slowing an aging clock) rather than just waiting for disease endpoints, accelerating clinical translation.
TRL
2/9Theoretical
Impact
5/5
Investment
2/5
Category
Ethics Security
